Clinical trials: Allergic Disease
Allergic Conjunctivitis
Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese Subjects
The purpose of the study is to demonstrate safety and efficacy of Olopatadine 0.2% compared to its vehicle in Japanese subjects in the treatment of acute allergen-mediated conjunctivitis using the conjunctival allergen challenge…
- Trial name
- NCT00987272
- Testing
- Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, Olopatadine Hydrochloride Ophthalmic Solution, 0.1%, Olopatadine 0.2% Vehicle
- Volunteers
- 267 people
- Sponsor
- Alcon Research
Asthma
A Safety and Efficacy Study of Inhaled R940343 in Patients With Mild to Moderate Asthma
The purpose of this study is to determine the safety, efficacy and tolerability of R940343 in the treatment of mild to moderate asthma.
- Trial name
- SITAR (NCT01591044)
- Testing
- R940343 1mg, R940343 2mg
- Where
- 59 sites in United States, Canada
- Volunteers
- 301 people
- Sponsor
- Rigel Pharmaceuticals
Rhinitis Allergic
MK0476 Study in Adult Patients With Allergic Rhinitis (0476-378)
The clinical study evaluates the efficacy and safety of MK0476 in adult patients with allergic rhinitis.
- Trial name
- NCT00446186
- Testing
- MK0476, montelukast sodium / Duration of Treatment: 2 Weeks
- Volunteers
- 945 people
- Sponsor
- Organon and Co
Allergic Rhinitis Due to Grass Pollen
Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber
The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber.
- Trial name
- NCT06104293
- Testing
- Grass Pollen Allergen Exposure
- Where
- France
- Volunteers
- 24 people
- Sponsor
- Alyatec
Hemophilia B, Allergic Reactions
Study to Describe the Allergic Reactions to Factor IX in Patients With Hemophilia B
Retrospective, multicenter study in patients with hemophilia B. This study will be placed at 20 to 50 hemophilia treatment centers in North America and the EU, and is designed to estimate the frequency of Class II and III…
- Trial name
- NCT00195221
- Where
- 38 sites in United States, Austria and 7 more
- Volunteers
- 166 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Atopic Dermatitis, Type 1 Hypersensitivity
Allergic Disease Onset Prevention Study
This is a Phase 1b/2, randomized, double-blind, multi-center study to evaluate the safety, tolerability, and preliminary clinical efficacy of STMC-103H in neonates and infants at risk for developing allergic disease (Type 1…
- Trial name
- adored (NCT05003804)
- Testing
- STMC-103H
- Where
- 31 sites in United States, Australia and 1 more
- Volunteers
- 283 people, healthy volunteers welcome
- Sponsor
- Siolta Therapeutics, Inc.
Allergic Rhinitis, Asthma
Comparative Real World Effectiveness of SQ Sublingual Immunotherapy (SLIT)-Tablets vs. Controls in Allergic Rhinitis and Asthma
To assess the impact of SQ SLIT-tablets (SQ Grass SLIT-tablet and SQ HDM SLIT-tablet) in Danish and Swedish allergic rhinitis (AR) patients, with or without asthma, between 2007-2020.
- Conditions
- Allergic Rhinitis, Asthma, Allergy
- Trial name
- RELY (NCT05476484)
- Testing
- SQ SLIT-tablet
- Where
- Denmark
- Volunteers
- 46,196 people
- Sponsor
- ALK-Abelló A/S
Allergy
Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Children Suffering From Grass Pollen Rhinoconjunctivitis
A phase III study to evaluate the efficacy and safety of SLIT for grass pollen allergens compared with placebo for reduction of symptoms and rescue medication usage in children.
- Trial name
- NCT00409409
- Testing
- 300 IR grass pollen allergen extract tablet
- Where
- Germany
- Volunteers
- 278 people
- Sponsor
- Stallergenes Greer
Seasonal Allergic Rhinitis
Phase II/III Seamless Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Treatment of Seasonal Allergic Rhinitis
A multicenter, randomized, double-blind, placebo-controlled Phase II/III seamless clinical study evaluating the efficacy, safety, pharmacokinetic (PK) profile, pharmacodynamic (PD) profile, and immunogenicity of MG-K10 humanized…
- Trial name
- NCT06846385
- Testing
- MG-K10 Humanized Monoclonal Antibody Injection
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Shanghai Mabgeek Biotech.Co.Ltd
Asthma, Allergic
Effects of Puressentiel Purifying Spray on Asthma Control in Patients With Mild to Moderate Allergy-induced Asthma.
The main objective of this study is to evaluate, in real life, the efficacy of prolonged use (6 months) of Puressentiel Air Purifying Spray with 41 essential oils on the control of allergy-induced asthma in the homes of patients…
- Trial name
- PSIndAC (NCT05352126)
- Testing
- Biocide
- Volunteers
- 80 people
- Sponsor
- Puressentiel
Peanut Allergy
A Study to Evaluate Safety, Tolerability and Immune Response in Adolescents Allergic to Peanut After Receiving Intradermal Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine
The purpose of this study is to evaluate the safety and tolerability of ASP0892 after intradermal (ID) injection in adolescent participants with peanut allergy.
- Trial name
- NCT03755713
- Testing
- ASP0892
- Where
- 7 sites in United States
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Asthma, Asthma Attack
Evaluating Asthma Exacerbation-induced Changes in Lung Function With a Home-based Spirometer
The investigators will study the use of a home-based spirometer (Spirobank Smart spirometer) that connects to a smartphone app (VitalFlo) in teenagers with persistent asthma to determine if clinically significant changes in lung…
- Conditions
- Asthma, Asthma Attack, Asthma, Allergic
- Trial name
- NCT03705325
- Testing
- Spirobank Smart spirometer
- Where
- 2 sites in United States
- Volunteers
- 44 people
- Sponsor
- VitalFlo Inc.
Rhinitis Allergic
Evaluation of Efficacy of Dellegra in Exposure Unit
Primary Objective: To collect and analyze clinical data of Allergic Rhinitis patients' Total Nasal Symptom Score (TNSS) change after Dellegra internal use under high density pure Japanese cedar pollen exposure.
- Trial name
- NCT02175485
- Testing
- Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg
- Where
- Japan
- Volunteers
- 24 people
- Sponsor
- Sanofi
Allergic Disease, Chronic Spontaneous Urticaria
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
This study aims to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) following a single subcutaneous injection of YH35324 in subjects with various allergic diseases.
- Conditions
- Allergic Disease, Chronic Spontaneous Urticaria, Chronic Inducible Urticaria, Cold Urticaria
- Trial name
- NCT05960708
- Testing
- YH35324, Omalizumab
- Where
- 9 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Yuhan Corporation
Rhinitis, Allergic, Perennial
Multicenter, Double-blind, Randomized, Placebo-controlled Study of Mometasone Furoate Nasal Spray in Pediatric Subjects With Perennial Allergic Rhinitis (Study P06332)
This is a multicenter, randomized, parallel design, double-blind study of mometasone furoate (MF) in pediatric subjects with perennial allergic rhinitis.
- Trial name
- NCT01135134
- Testing
- Mometasone furoate
- Volunteers
- 333 people
- Sponsor
- Organon and Co
Seasonal Allergic Rhinitis
Study of ACT-129968 in Adult Patients With Seasonal Allergic Rhinitis
This study will assess the efficacy and safety of different doses of ACT-129968 in adult patients with seasonal allergic rhinitis, due to mountain cedar pollen.
- Trial name
- SAR (NCT01241214)
- Testing
- ACT-129968, Cetirizine
- Where
- 7 sites in United States
- Volunteers
- 579 people
- Sponsor
- Idorsia Pharmaceuticals Ltd.
Allergic Rhinitis
Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age
The purpose of the study is to assess the safety of the study drug, Patanase (Olopatadine Hydrochloride Nasal Spray 0.6%) compared to placebo (inactive substance) in children ages 2 to less than 6 who have a history of nasal…
- Trial name
- NCT00794144
- Testing
- Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
- Where
- United States
- Volunteers
- 132 people
- Sponsor
- Alcon Research
Perennial Allergic Rhinitis
A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis
The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and…
- Trial name
- NCT01425632
- Testing
- TAU-284
- Where
- 5 sites in Japan
- Volunteers
- 490 people
- Sponsor
- Tanabe Pharma Corporation
Allergic Rhinitis, Allergic Rhinoconjunctivitis
SUBLIVAC FIX Birch Dose Tolerability/Dose Range Finding
The aim of the study is to determine the optimal effective dose of SUBLIVAC FIX Birch based on reduction of upper airways reactivity after 5 months of treatment with different dosages of SUBLIVAC FIX Birch compared to placebo.
- Trial name
- NCT01639768
- Testing
- SUBLIVAC FIX Birch
- Where
- 20 sites in Czechia, Germany and 1 more
- Volunteers
- 270 people
- Sponsor
- HAL Allergy
Type I Hypersensitivity
Induction of Immunogenicity With Different Doses of TreeMATA in Subjects Allergic to Tree Pollen
Tree MATA (modified pollen allergen tyrosine adsorbate) has been developed to provide pre-seasonal specific immunotherapy for patients with hypersensitivity to tree (birch, alder, and hazel) pollen.
- Trial name
- NCT00113750
- Testing
- TreeMATA MPL
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Allergy Therapeutics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.